Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
토요일, 8월 22

Elevance Health Inc

ELVNYSE
Trade with Public
Trade with Public
$400.54
4.261.07%
가까이에: Aug 21, 5:00 PM EST
$400.55
0.010%
시간외: 7:06 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황배당금비교옵션주식 보고서

Elevance Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elevance Health (ELV).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

14Buy
6Hold
Consensus RatingBuy# Analysts20Avg. Consensus PT$438Upside to Avg. PT+9.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 17, 2026Leerink PartnersWhit MayoPT RaiseMarket Perform$364→$395
Jul 16, 2026RBC CapitalBen HendrixPT CutSector Perform$439→$424
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

Leerink Partners analyst Whit Mayo maintains Elevance Health (NYSE:ELV) with a Market Perform and raises the price target from $364 to $395.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and lowers the price target from $439 to $424.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $492 to $473.
Benzinga Newsdesk

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.
Avi Kapoor

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $480 to $457.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved